<DOC>
	<DOCNO>NCT00577018</DOCNO>
	<brief_summary>The purpose study determine safety profile 4 mg prucalopride treatment chronic constipation .</brief_summary>
	<brief_title>Efficacy Safety Study Effect Dose-Titration Prucalopride The Treatment Chronic Constipation</brief_title>
	<detailed_description>To evaluate potential difference adverse event ( safety ) profile 4 mg prucalopride daily 4 week ; titration 4-mg total daily dose prucalopride start 1 mg 2 day , 2 mg 2 day , 4 mg thereafter ; placebo give oral tablet daily 4 week patient chronic constipation</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Male nonpregnant , nonbreast feed female subject least 18 year age ( upper age limit ) ; History constipation . The subject report average , 2 few spontaneous bowel movement per week result feeling sensation complete evacuation , well occurrence one follow least 6 month selection visit : hard ( little ball ) and/or hard stool least quarter stool ; sensation incomplete evacuation follow least quarter stool ; strain defecation least quarter time . The criterion apply spontaneous bowel movement , ( i.e. , precede within period 24 hour intake laxative use enema ) . A subject never spontaneous bowel movement consider constipate therefore eligible trial ; Constipation functional ( i.e. , secondary cause ) ; Willingness ability fill diary questionnaire ; Written inform consent , sign subject legally acceptable representative investigator ; Availability followup trial period , determine protocol . Subjects constipation thought druginduced use disallowed medication ; Subjects suffer secondary cause chronic constipation . For example : Endocrine disorder : insulindependent diabetes mellitus ; hypopituitarism ; hypothyroidism ; hypercalcemia ; pseudohypoparathyroidism ; pheochromocytoma ; glucagonproducing tumor . Endocrine disorder control appropriate medical therapy exclude , exception insulindependent diabetes mellitus Metabolic disorder : porphyria ; uremia ; hypokalemia ; amyloid neuropathy . Metabolic disorder control appropriate medical therapy exclude • Exclusion criterion ( cont 'd ) : Neurologic disorder : Parkinson 's disease ; cerebral tumor ; cerebrovascular accident ; multiple sclerosis ; meningocele ; aganglionosis ; hypoganglionosis ; hyperganglionosis ; autonomic neuropathy ; spinal cord injury ; Chagas ' disease ; major depression Presence megacolon/megarectum diagnosis pseudoobstruction ; Constipation result surgery ; Known suspect organic disorder large bowel ( i.e. , obstruction , carcinoma , inflammatory bowel disease ) . Results barium enema flexible sigmoidoscopy colonoscopic examination perform within last 12 month need rule organic disorder . An examination perform within last 3 year acceptable , examination perform evaluation constipation , history evidence weight loss , anemia , rectal bleeding , subject three consecutively negative stool occult blood test screen . Subjects polyps discover colonoscopy untreated ( i.e. , polypectomy ) exclude ; Presence severe clinically uncontrolled cardiovascular , liver lung disease , neurologic psychiatric disorder ( include active alcohol drug abuse ) ; Clinically significant cancer within past 5 year ; Known HIVpositive status AIDS ; Impaired renal function ; Clinically significant abnormality hematology , urinalysis blood chemistry ; Females childbearing potential without adequate contraceptive protection trial . Oral contraceptive , DepoProvera® , Norplant® ) must use least 3 month prior randomization . I.U.D . 's , sterilization , doublebarrier method acceptable method birth control ; Treatment investigational drug 30 day precede runin phase trial ; Previous treatment either R093877 ( prucalopride hydrochloride ) R108512 ( prucalopride succinate ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>